The role of TIM-3 in sepsis: a promising target for immunotherapy?

Front Immunol. 2024 Mar 21:15:1328667. doi: 10.3389/fimmu.2024.1328667. eCollection 2024.

Abstract

Sepsis remains a significant cause of mortality and morbidity worldwide, with limited effective treatment options. The T-cell immunoglobulin and mucin domain-containing molecule 3 (TIM-3) has emerged as a potential therapeutic target in various immune-related disorders. This narrative review aims to explore the role of TIM-3 in sepsis and evaluate its potential as a promising target for immunotherapy. We discuss the dynamic expression patterns of TIM-3 during sepsis and its involvement in regulating immune responses. Furthermore, we examine the preclinical studies investigating the regulation of TIM-3 signaling pathways in septic models, highlighting the potential therapeutic benefits and challenges associated with targeting TIM-3. Overall, this review emphasizes the importance of TIM-3 in sepsis pathogenesis and underscores the promising prospects of TIM-3-based immunotherapy as a potential strategy to combat this life-threatening condition.

Keywords: Sepsis; TIM-3; immunotherapy; inflammatory response; therapeutic target.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Hepatitis A Virus Cellular Receptor 2* / metabolism
  • Humans
  • Immunotherapy
  • Sepsis* / therapy
  • Signal Transduction

Substances

  • Hepatitis A Virus Cellular Receptor 2
  • HAVCR2 protein, human

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported by the Fund Project of National Natural Science Foundation of China (81671887 to Lulong Bo, 81701885 to Baoji Hu, 82302421 to Changli Wang), Shanghai Science and Technology Committee Rising-Star Program (19QA1408500 to Lulong Bo) and the Priority Speciality of Shanghai Pudong Hospital (Zdzk2024-07 to Baoji Hu).